Key result
In patients with treatment-resistant hypertension, renal denervation significantly reduced office blood pressure by 22/9 mmHg and daytime ambulatory blood pressure by 12/7 mmHg.
Why the study?
Does renal denervation reduce blood pressure in patients with treatment-resistant hypertension?
Observational (n=253)
Open-label
Yes
Does renal denervation reduce blood pressure in patients with treatment-resistant hypertension?
In a real-world UK registry of patients with treatment-resistant hypertension, renal denervation was associated with significant reductions in both office and ambulatory blood pressure, which were not explained by medication changes.
Answers are grounded in this paper and cite their sources.
Supports renal denervation evaluation in resistant hypertension; leaves open need for randomized confirmation.
BACKGROUND: Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response-particularly in those prescribed aldosterone antagonists at the time of RDN. METHODS: We examined all patients treated with RDN for treatment-resistant hypertension in 18 UK centres. RESULTS: Results from 253 patients treated with five technologies are shown. Pre-procedural mean office BP (OBP) was 185/102 mmHg (SD 26/19; n = 253) and mean daytime ABP was 170/98 mmHg (SD 22/16; n = 186). Median number of antihypertensive drugs was 5.0: 96 % ACEi/ARB; 86 % thiazide/loop diuretic and 55 % aldosterone antagonist. OBP, available in 90 % at 11 months follow-up, was 163/93 mmHg (reduction of 22/9 mmHg). ABP, available in 70 % at 8.5 months follow-up, was 158/91 mmHg (fall of 12/7 mmHg). Mean drug changes post RDN were: 0.36 drugs added, 0.91 withdrawn. Dose changes appeared neutral. Quartile analysis by starting ABP showed mean reductions in systolic ABP after RDN of: 0.4; 6.5; 14.5 and 22.1 mmHg, respectively (p < 0.001 for trend). Use of aldosterone antagonist did not predict response (p > 0.2). CONCLUSION: In 253 patients treated with RDN, office BP fell by 22/9 mmHg. Ambulatory BP fell by 12/7 mmHg, though little response was seen in the lowermost quartile of starting blood pressure. Fall in BP was not explained by medication changes and aldosterone antagonist use did not affect response.
No takes yet. Share an insight, caveat, or question.
Sharp et al. (2016) conducted an observational in Treatment-resistant hypertension (n=253). Renal artery sympathetic denervation vs. Baseline (before-after comparison) was evaluated on Change in office blood pressure (reduction of 22/9 mmHg, p=<0.001). In patients with treatment-resistant hypertension, renal denervation significantly reduced office blood pressure by 22/9 mmHg and daytime ambulatory blood pressure by 12/7 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: